Document Detail

The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
MedLine Citation:
PMID:  10208431     Owner:  NLM     Status:  MEDLINE    
The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leukemia, joining the AML1 gene on chromosome 21, to the ETO gene on chromosome 8, forming the AML1/ETO fusion gene. The AMLI/ETO fusion protein has been shown to function mainly as a transcriptional repressor of AML1 target genes and to block AML1 function in vitro and in vivo. However, AML1/ETO can also activate the BCL-2 promoter and cause enhanced hematopoietic progenitor self-renewal in vitro, suggesting gain-of-functions unique to the fusion protein. We used NIH3T3 cells to determine the transforming capacity of AML1/ETO, and to further characterize its mechanism of action. Expression of AML1/ETO in NIH3T3 cells caused cell-type specific cell death, and cellular transformation, characterized by phenotypic changes, anchorage-independent growth, and tumor formation in nude mice. In contrast, neither expression of AML1A, AML1B or ETO altered the normal growth pattern of the cells. To investigate the mechanism of transformation by AML1/ETO, we analysed the levels of activated, phosphorylated c-Jun (ser63) and other constituents of the AP-1 complex, in the presence of various AML1/ETO related proteins. Expression of AML1/ETO increased the level of c-Jun-P (ser63), and activated AP-1 dependent transcription, which was inhibited by expression of a dominant-negative c-Jun protein. Mutational analysis revealed that the runt homology domain (RHD) and a C-terminal transcriptional repression domain in AML1/ETO are required for transformation, activation of c-Jun and increased AP-1 activity. These results establish the transforming potential of the t(8;21) fusion protein and link this gain-of-function property to modulation of AP-1 activity.
R C Frank; X Sun; F J Berguido; A Jakubowiak; S D Nimer
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Oncogene     Volume:  18     ISSN:  0950-9232     ISO Abbreviation:  Oncogene     Publication Date:  1999 Mar 
Date Detail:
Created Date:  1999-06-01     Completed Date:  1999-06-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8711562     Medline TA:  Oncogene     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1701-10     Citation Subset:  IM    
Sloan Kettering Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3T3 Cells
Cell Division
Cell Transformation, Neoplastic
Chromosomes, Human, Pair 21*
Chromosomes, Human, Pair 8*
Core Binding Factor Alpha 2 Subunit
DNA-Binding Proteins / genetics,  metabolism
Gene Expression
Oncogene Proteins, Fusion*
Proto-Oncogene Proteins*
Proto-Oncogene Proteins c-jun / metabolism
Recombinant Fusion Proteins / genetics,  metabolism
Structure-Activity Relationship
Transcription Factor AP-1 / metabolism*
Transcription Factors / genetics,  metabolism*
Translocation, Genetic*
Grant Support
Reg. No./Substance:
0/AML1-ETO fusion protein, human; 0/Core Binding Factor Alpha 2 Subunit; 0/DNA-Binding Proteins; 0/Oncogene Proteins, Fusion; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-jun; 0/RUNX1 protein, human; 0/RUNX1T1 protein, human; 0/Recombinant Fusion Proteins; 0/Runx1 protein, mouse; 0/Transcription Factor AP-1; 0/Transcription Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stim...
Next Document:  Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-le...